α7-nicotinic acetylcholine receptor (α7-nAChR) agonists have entered clinical trials as pro-cognitive agents for treating schizophrenia and AD (Stoiljkovic et al., 2015; Townsend et al., 2016). This evidence concerns the gene CHRNA7 and schizophrenia.